Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Imatinib and type 2 diabetes.

David Dingli¹, Robert C Wolf, Adrian Vella

¹Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, Minnesota 55905, USA.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

|May 11, 2007

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

More Than Stress Hyperglycemia: Acute Pancreatitis as a Prelude to Diabetes.

Diabetes care·2026

Same author

Pregnancies Affected by Diabetes in Teenagers and Emerging Adults: A Population-Based Study.

Metabolic syndrome and related disorders·2026

Same author

Integrated glucagon model for estimation of α-cell responsivity to glucose and amino acids during graded glucose infusion.

American journal of physiology. Endocrinology and metabolism·2026

Same author

Hepatic steatosis in humans is associated with preserved glucagon action on amino acid metabolism.

The Journal of clinical investigation·2025

Same author

Modeling the effect of glucagon on endogenous glucose production in healthy individuals under meal-like conditions.

American journal of physiology. Regulatory, integrative and comparative physiology·2025

Same author

Cardiovascular autonomic neuropathy defined by indices of heart rate variability is associated with cardiovascular disease: a longitudinal cohort study of participants with type 1 diabetes.

Cardiovascular diabetology·2025

Same journal

Tirzepatide versus conventional GLP-1 receptor agonists for treatment simplification in type 2 diabetes mellitus: a real-world study.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026

Same journal

Risk-stratification of pediatric thyroid nodules using ATA and ACR TIRADS adult thyroid nodule scoring systems.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026

Same journal

Effectiveness of GLP-1 receptor agonists and SGLT-2 inhibitors combination therapy in type 2 diabetes: a real world experience.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026

Same journal

North American Society for Interventional Thyroidology (NASIT) Statement on Directed Ablative Therapy for the Management of of Low Risk Papillary Thyroid Carcinoma.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026

Same journal

Lower Cutoffs Improve the Diagnostic Performance of DDAVP-Stimulated Bilateral Inferior Petrosal Sinus Sampling for Cushing Disease: A Prospective Cohort Study.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026

Same journal

Efficacy of Initiation of Semaglutide versus SGLT2 inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multicenter Propensity-Matched Real-World Study.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026

See all related articles

Imatinib mesylate, used for chronic myeloid leukemia, does not appear to significantly impact glycemic control in patients with type 2 diabetes. This study found no net effect on diabetes management in patients receiving imatinib therapy.

Area of Science:

Pharmacology
Endocrinology
Oncology

Background:

Imatinib mesylate is a tyrosine kinase inhibitor used for chronic myeloid leukemia.
Previous reports suggested potential benefits of imatinib on glycemic control in type 2 diabetes.

Purpose of the Study:

To investigate the effect of imatinib mesylate on type 2 diabetes.
To characterize any impact on glycemic control in patients undergoing imatinib treatment.

Main Methods:

Retrospective review of 164 patients receiving imatinib at Mayo Clinic (1999-2004).
Identification of patients with type 2 diabetes (preexisting or developed during treatment).
Analysis of biochemical data before, during, and after imatinib therapy.

Main Results:

Related Experiment Videos

Seven patients had pre-existing type 2 diabetes; two developed diabetes during imatinib treatment.
No significant net effect on glycemic control or diabetes therapy was observed in the study cohort.
Findings contrast with some previous reports on imatinib's effect on diabetes.

Conclusions:

Imatinib mesylate is unlikely to substantially affect glycemic control in patients with type 2 diabetes.
Further research may be needed to fully elucidate the relationship between imatinib and diabetes.